ESMO-Preceptorship-Head-and-Neck-Cancer-2022-1000x250-september

Start date: 23 Sep 2022
End date: 24 Sep 2022
Location: Singapore, Republic of Singapore

Learning Objectives

To understand epidemiology, aetiology and molecular biology of nasopharyngeal cancer and squamous cell carcinoma of the head and neck (HNSCC)
To understand multidisciplinary management and treatment of head and neck cancer
To learn about advances in the treatment and novel targets in head and neck cancer

Accreditation

The programme of this event has been accredited with 11 ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to ESMO-MORA Recertification Process & Requirements.

Co-Chairs

Boon-Cher Goh, Singapore
Jean-Pascal Machiels, Belgium

Learning Objectives

Accreditation

Co-Chairs

You may also be interested in...